MitrAssist offers a minimally invasive approach to mitral regurgitation treatment.
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality.MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 3, 2020 | Series Unknown | $50M | 1 | — | — | Detail |
Nov 11, 2017 | Series Unknown | $30M | 2 | Fosun International | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Fosun International | Yes | Series Unknown |
Ping An | — | Series Unknown |